ISPOR ONCOLOGY SPECIAL INTEREST GROUP- IMPROVING THE AVAILABILITY AND QUALITY OF UTILITY ESTIMATES FOR THE POST-PROGRESSION PERIOD IN ONCOLOGY MODELS- RECOMMENDATIONS BASED ON A SYSTEMATIC REVIEW
Author(s)
Speakers: Sorrel Wolowacz, PhD, Head, EU Health Economics, RTI Health Solutions, Manchester, UK Agnes Benedict, MSc, Executive Director, Evidera Inc., Budapest, Hungary; Khalid M Kamal, MPharm, PhD, Professor, Division of Pharmaceutical, Administrative and Social Sciences, Duquesne University School of Pharmacy, Pittsburgh, PA, USA
Presentation Documents
The forum discusses a systematic review of utility estimates for the post-progression period for all oncology indications.
The Discussion Leaders will present:
- An overview of the methods and results: Out of a total of 4,839 published articles and 176 HTAs in all oncology indications; 350 publications and 60 technology appraisals were included.
- Review included details on study type, utility measure, sample size, number and timing of assessments, quality assessments, potential biases, utility estimates of caregivers/family members, and approaches to modeling post-progression period
- Challenges/opportunities for collecting high quality utility data post-progression in RCTs and observational studies, including insights from an oncologist and ASCO member
- Some “good practice” examples, and recommendations for future studies
This forum will be of value for researchers interested in QoL research, health utility estimation, economic evaluation and/or HTA in oncology indications. Participants are invited to contribute to the discussion and make suggestions for future research methods.
Conference/Value in Health Info
2019-05, ISPOR 2019, New Orleans, LA, USA